BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 26941577)

  • 1. Palmitate-induced Regulation of PPARγ via PGC1α: a Mechanism for Lipid Accumulation in the Liver in Nonalcoholic Fatty Liver Disease.
    Maruyama H; Kiyono S; Kondo T; Sekimoto T; Yokosuka O
    Int J Med Sci; 2016; 13(3):169-78. PubMed ID: 26941577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palmitate induces fat accumulation by activating C/EBPβ-mediated G0S2 expression in HepG2 cells.
    Zhao NQ; Li XY; Wang L; Feng ZL; Li XF; Wen YF; Han JX
    World J Gastroenterol; 2017 Nov; 23(43):7705-7715. PubMed ID: 29209111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiepileptic Drug-Activated Constitutive Androstane Receptor Inhibits Peroxisome Proliferator-Activated Receptor
    Shizu R; Otsuka Y; Ezaki K; Ishii C; Arakawa S; Amaike Y; Abe T; Hosaka T; Sasaki T; Kanno Y; Miyata M; Yamazoe Y; Yoshinari K
    Mol Pharmacol; 2020 Nov; 98(5):634-647. PubMed ID: 32892155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of individual and multiple fatty acids (palmitate, oleate and docosahaexenoic acid) on cell viability and lipid metabolism in LO2 human liver cells.
    Chen L; Wang C; Huang S; Gong B; Yu J; Shi Q; Chen G
    Mol Med Rep; 2014 Dec; 10(6):3254-60. PubMed ID: 25241938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a/PPARγ axis in non-alcoholic fatty liver disease.
    Liu J; Tang T; Wang GD; Liu B
    Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31064820
    [No Abstract]   [Full Text] [Related]  

  • 6. Dietary fat supply to failing hearts determines dynamic lipid signaling for nuclear receptor activation and oxidation of stored triglyceride.
    Lahey R; Wang X; Carley AN; Lewandowski ED
    Circulation; 2014 Nov; 130(20):1790-9. PubMed ID: 25266948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Scutellarin ameliorates nonalcoholic fatty liver disease through the PPARγ/PGC-1α-Nrf2 pathway.
    Zhang X; Ji R; Sun H; Peng J; Ma X; Wang C; Fu Y; Bao L; Jin Y
    Free Radic Res; 2018 Feb; 52(2):198-211. PubMed ID: 29400110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cichoric Acid Prevents Free-Fatty-Acid-Induced Lipid Metabolism Disorders via Regulating Bmal1 in HepG2 Cells.
    Guo R; Zhao B; Wang Y; Wu D; Wang Y; Yu Y; Yan Y; Zhang W; Liu Z; Liu X
    J Agric Food Chem; 2018 Sep; 66(37):9667-9678. PubMed ID: 30036051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nimesulide, a cyclooxygenase-2 selective inhibitor, suppresses obesity-related non-alcoholic fatty liver disease and hepatic insulin resistance through the regulation of peroxisome proliferator-activated receptor γ.
    Tsujimoto S; Kishina M; Koda M; Yamamoto Y; Tanaka K; Harada Y; Yoshida A; Hisatome I
    Int J Mol Med; 2016 Sep; 38(3):721-8. PubMed ID: 27431935
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic Regulation of Peroxisome Proliferator-Activated Receptor Gamma Mediates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease.
    Hajri T; Zaiou M; Fungwe TV; Ouguerram K; Besong S
    Cells; 2021 May; 10(6):. PubMed ID: 34072832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats.
    Zhang Y; Cui Y; Wang XL; Shang X; Qi ZG; Xue J; Zhao X; Deng M; Xie ML
    Cytokine; 2015 Sep; 75(1):127-35. PubMed ID: 26194065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Water Extract of Dolichos lablab Attenuates Hepatic Lipid Accumulation in a Cellular Nonalcoholic Fatty Liver Disease Model.
    Im AR; Kim YH; Lee HW; Song KH
    J Med Food; 2016 May; 19(5):495-503. PubMed ID: 27152979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of plasma free fatty acids upregulates peroxisome proliferator-activated receptor (PPAR) alpha and delta and PPAR coactivator 1alpha in human skeletal muscle, but not lipid regulatory genes.
    Watt MJ; Southgate RJ; Holmes AG; Febbraio MA
    J Mol Endocrinol; 2004 Oct; 33(2):533-44. PubMed ID: 15525607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
    Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
    Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro.
    Burgermeister E; Schnoebelen A; Flament A; Benz J; Stihle M; Gsell B; Rufer A; Ruf A; Kuhn B; Märki HP; Mizrahi J; Sebokova E; Niesor E; Meyer M
    Mol Endocrinol; 2006 Apr; 20(4):809-30. PubMed ID: 16373399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells.
    Rogue A; Anthérieu S; Vluggens A; Umbdenstock T; Claude N; de la Moureyre-Spire C; Weaver RJ; Guillouzo A
    Toxicol Appl Pharmacol; 2014 Apr; 276(1):73-81. PubMed ID: 24534255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual peroxisome-proliferator-activated-receptor-α/γ activation inhibits SIRT1-PGC1α axis and causes cardiac dysfunction.
    Kalliora C; Kyriazis ID; Oka SI; Lieu MJ; Yue Y; Area-Gomez E; Pol CJ; Tian Y; Mizushima W; Chin A; Scerbo D; Schulze PC; Civelek M; Sadoshima J; Madesh M; Goldberg IJ; Drosatos K
    JCI Insight; 2019 Aug; 5(17):. PubMed ID: 31393858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatocyte-specific Nrf2 deficiency mitigates high-fat diet-induced hepatic steatosis: Involvement of reduced PPARγ expression.
    Li L; Fu J; Liu D; Sun J; Hou Y; Chen C; Shao J; Wang L; Wang X; Zhao R; Wang H; Andersen ME; Zhang Q; Xu Y; Pi J
    Redox Biol; 2020 Feb; 30():101412. PubMed ID: 31901728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of apolipoprotein A5 in non-alcoholic fatty liver disease.
    Ress C; Moschen AR; Sausgruber N; Tschoner A; Graziadei I; Weiss H; Schgoer W; Ebenbichler CF; Konrad RJ; Patsch JR; Tilg H; Kaser S
    Gut; 2011 Jul; 60(7):985-91. PubMed ID: 21339203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urokinase-type plasminogen activator (uPA) stimulates triglyceride synthesis in Huh7 hepatoma cells via p38-dependent upregulation of DGAT2.
    Paland N; Gamliel-Lazarovich A; Coleman R; Fuhrman B
    Atherosclerosis; 2014 Nov; 237(1):200-7. PubMed ID: 25244504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.